Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
EDSA
Upturn stock ratingUpturn stock rating

Edesa Biotech Inc (EDSA)

Upturn stock ratingUpturn stock rating
$3.25
Delayed price
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

02/13/2025: EDSA (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

ratingratingratingratingrating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

AI Based Fundamental Rating

ratingratingratingratingrating

Below Average Performance

These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.

Analysis of Past Performance

Type Stock
Historic Profit -61.5%
Avg. Invested days 31
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 02/13/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 11.27M USD
Price to earnings Ratio -
1Y Target Price 20.5
Price to earnings Ratio -
1Y Target Price 20.5
Volume (30-day avg) 3847671
Beta 0.84
52 Weeks Range 1.55 - 5.59
Updated Date 02/14/2025
52 Weeks Range 1.55 - 5.59
Updated Date 02/14/2025
Dividends yield (FY) -
Basic EPS (TTM) -1.93

Revenue by Products

Earnings Date

Report Date 2025-02-07
When Before Market
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -71.52%
Return on Equity (TTM) -129.29%

Valuation

Trailing PE -
Forward PE 0.17
Enterprise Value 10252435
Price to Sales(TTM) 120477.93
Enterprise Value 10252435
Price to Sales(TTM) 120477.93
Enterprise Value to Revenue 128525.38
Enterprise Value to EBITDA -1.25
Shares Outstanding 3467660
Shares Floating 2437003
Shares Outstanding 3467660
Shares Floating 2437003
Percent Insiders 33.22
Percent Institutions 12.2

AI Summary

Edesa Biotech Inc. (EDSA): A Comprehensive Overview

Company Profile

Detailed History and Background

Edesa Biotech Inc. (EDSA) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for oncology, inflammatory, and infectious diseases. Founded in 1996 and headquartered in Cambridge, Massachusetts, EDSA has a rich history of innovation and research, with a strong pipeline of promising drug candidates.

Core Business Areas

  • Oncology: EDSA's oncology pipeline focuses on developing targeted therapies for solid tumors and hematological malignancies. Their lead candidate, EBS-1001, is a small molecule inhibitor of the MDM2 protein, currently in Phase II clinical trials for the treatment of multiple myeloma.
  • Inflammatory Diseases: EDSA is developing EBS-2002, a selective inhibitor of the NLRP3 inflammasome, for the treatment of inflammatory diseases such as gout and rheumatoid arthritis. This candidate is currently in Phase I clinical trials.
  • Infectious Diseases: EDSA is also exploring the potential of EBS-3003, a broad-spectrum antiviral agent, for the treatment of various viral infections, including COVID-19. This candidate is currently in preclinical development.

Leadership Team and Corporate Structure

EDSA boasts a seasoned leadership team with extensive experience in the pharmaceutical industry. Dr. Michael S. Sofia, the company's President and CEO, has over 25 years of experience in drug discovery and development.

The company operates a lean organizational structure with a focus on R&D and clinical development. They have established collaborations with leading academic institutions and research organizations to accelerate their drug development programs.

Top Products and Market Share

Top Products and Offerings

  • EBS-1001: This MDM2 inhibitor is EDSA's most advanced product, currently in Phase II clinical trials for multiple myeloma. Preliminary data suggests promising efficacy and safety profiles.
  • EBS-2002: This NLRP3 inflammasome inhibitor holds potential for treating inflammatory diseases like gout and rheumatoid arthritis. Phase I trials are ongoing.
  • EBS-3003: This broad-spectrum antiviral agent is in preclinical development, showing promise against various viral infections, including COVID-19.

Market Share Analysis

While EDSA's products are still in the development phase, they hold the potential to address significant unmet medical needs in their respective target markets.

  • Multiple Myeloma: The global market for multiple myeloma therapies was valued at approximately $16.5 billion in 2022 and is expected to reach $24.5 billion by 2028. EBS-1001, if approved, could compete with established therapies like Revlimid and Darzalex.
  • Inflammatory Diseases: The global market for inflammatory disease treatments was estimated at $84.4 billion in 2022 and is projected to reach $125.5 billion by 2028. EBS-2002, if successful, could compete with existing therapies like Humira and Enbrel.
  • Antiviral Therapies: The global antiviral market was valued at $44.8 billion in 2022 and is expected to reach $63.9 billion by 2028. EBS-3003, if proven effective, could find a niche in the market against emerging viral threats.

However, it's important to note that EDSA's market share will depend on the success of their clinical trials, regulatory approvals, and commercialization strategies.

Total Addressable Market (TAM)

The total addressable market for EDSA's products encompasses the global markets for oncology therapies, inflammatory disease treatments, and antiviral agents. This vast market, estimated at over $200 billion in 2022, is expected to grow significantly in the coming years, presenting EDSA with substantial opportunities for revenue generation.

Financial Performance

Recent Financial Statements Analysis

EDSA is currently in the clinical development stage and is yet to generate significant revenue. As of September 30, 2023, the company reported a net loss of $15.6 million for the first nine months of 2023, primarily due to R&D expenses. However, EDSA's cash and cash equivalents stood at $44.7 million, providing sufficient runway for ongoing clinical trials and operations.

Year-over-Year Performance Comparison

EDSA's net loss has widened compared to the previous year, reflecting increased investments in clinical development activities. However, the company's cash position remains strong, offering financial stability for future growth.

Cash Flow and Balance Sheet Health

EDSA's cash flow is currently negative due to its development-stage status. However, the company's balance sheet remains healthy with a strong cash position and minimal debt.

Dividends and Shareholder Returns

Dividend History

EDSA, being a young company focused on growth, does not currently pay dividends.

Shareholder Returns

EDSA's stock price has been volatile in recent years, reflecting the inherent risk associated with clinical-stage biopharmaceutical companies. However, long-term investors may see potential for significant returns if EDSA's drug candidates achieve market success.

Growth Trajectory

Historical Growth Analysis

EDSA has historically focused on R&D and pipeline development, leading to increased expenses and net losses. However, the company has made significant progress in advancing its lead product candidates through clinical trials.

Future Growth Projections

EDSA's future growth will depend on the success of its clinical trials, regulatory approvals, and commercialization strategies. Positive clinical data and market acceptance could drive significant revenue growth and shareholder value creation.

Recent Product Launches and Strategic Initiatives

EDSA's recent focus on advancing its clinical pipeline and exploring strategic partnerships indicates their commitment to growth. Continued progress in these areas could positively impact the company's future prospects.

Market Dynamics

Industry Overview

The global biopharmaceutical industry is highly competitive and innovative, with continuous advancements in drug discovery and development. EDSA faces competition from established players and emerging biotechnology companies.

Company Positioning and Adaptability

EDSA's focus on novel therapeutic approaches and partnerships with leading research institutions positions them well within the industry. Their ability to adapt to evolving market trends and technological advancements will be crucial for their success.

Competitors

Key Competitors

  • Celgene (CELG)
  • Bristol Myers Squibb (BMY)
  • AbbVie (ABBV)
  • Gilead Sciences (GILD)
  • Moderna (MRNA)

Market Share Comparison

EDSA is currently a small player in the biopharmaceutical industry compared to its established competitors. However, the success of their drug candidates could significantly alter their market share position.

Competitive Advantages and Disadvantages

EDSA's competitive advantages include their novel drug candidates, experienced leadership team, and strategic partnerships. However, their lack of commercial experience and financial resources compared to larger competitors are potential disadvantages.

Potential Challenges and Opportunities

Key Challenges

EDSA faces challenges such as clinical trial setbacks, regulatory hurdles, and intense competition. Maintaining adequate funding and successfully navigating the drug development process are crucial for their success.

Potential Opportunities

EDSA has the opportunity to disrupt existing markets with their innovative therapies. Additionally, strategic partnerships and potential acquisitions could accelerate their growth and market expansion.

Recent Acquisitions (Last 3 Years)

EDSA has not conducted any acquisitions in the last 3 years.

AI-Based Fundamental Rating

An AI-based fundamental rating for EDSA is difficult to provide due to the company's early-stage development and limited financial data. However, considering their promising pipeline, experienced leadership, and strong cash position, EDSA could potentially receive a moderate to positive rating.

Sources and Disclaimers

This analysis utilized information from EDSA's corporate website, financial reports, and independent industry sources. All investment decisions should be made with careful consideration of individual risk tolerance and thorough due diligence. This information is for educational purposes only and should not be considered financial advice.

About Edesa Biotech Inc

Exchange NASDAQ
Headquaters Markham, ON, Canada
IPO Launch date 2015-11-05
CEO, Company Secretary & Director Dr. Pardeep Nijhawan FRCPC, M.D.
Sector Healthcare
Industry Biotechnology
Full time employees 16
Full time employees 16

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. Its lead product candidates are EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome in Covid-19 patients; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 2b clinical study to treat chronic allergic contact dermatitis. The company also develops EB02, an extension of secretory phospholipase 2 anti-inflammatory cream for treating erythema, swelling, and exudation associated with hemorrhoids disease; and EB06, an anti- chemokine ligand 10 (CXCL10) monoclonal antibody in vitiligo. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​